Renin-Angiotensin-System (RAS)-Acting Agents Market Trends 2025-2034: Growth, Strategic Insights, and Opportunities Ahead
Get 30% off on our Global Market Reports with code ONLINE30 – Hurry, limited time offer!
How Has The Renin-Angiotensin-System (RAS)-Acting Agents Market Growth Evolved From 2024 To 2025, And What’s Ahead?
In recent times, the market size of renin-angiotensin-system (RAS)-acting agents has seen substantial growth. It’s forecasted to escalate from $5.82 billion in 2024 to $6.17 billion in 2025, with a compound annual growth rate (CAGR) of 6.0%. This growth over the historical period is linked to various factors such as the rising cases of hypertension, growing incidences of cardiovascular diseases, an increase in the aging population, greater consciousness regarding the management of blood pressure, robust support from clinical research, and the approval of new drugs by regulatory bodies.
The market for agents that act on the renin-angiotensin system (RAS) is predicted to experience substantial growth in the upcoming years. Its value is projected to hit $7.73 billion by 2029, with an expected compound annual growth rate (CAGR) of 5.8%. This projected surge over the forecast period can be credited to several factors such as an increased emphasis on personalized treatment, soaring demand for fixed-dose combinations, escalated investment in cardiovascular studies, expanding access to healthcare in emerging economies, and a growing incidence of diseases tied to lifestyle choices. Key trends expected to shape this market during the forecast period include the application of artificial intelligence (AI) in drug discovery, delivery of drugs using nanotechnology, advancements in personalized medicine, using blockchain for secure clinical data sharing, hypertension monitoring through wearable biosensors, and employing digital twin technology for patient simulation.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Renin-Angiotensin-System (RAS)-Acting Agents Market?
The escalating occurrence of hypertension is projected to stimulate the expansion of the renin-angiotensin system (RAS)-acting agents market in the future. Hypertension, also known as high blood pressure, signifies a continuous health situation where the pressure against the arterial walls remains excessively high. This occurrence happens primarily due to unhealthy eating habits, especially those involving high salt and processed food consumption that lead to blood pressure surge and cardiovascular system strain. RAS-acting agents play a crucial role in curbing hypertension incidence by controlling blood pressure through the restriction of angiotensin II, a hormone responsible for blood vessel constriction and fluid retention, which in effect facilitates vasodilation and a consequent decrease in blood pressure. For example, in October 2024, data from the Australian Bureau of Statistics, an Australia-based governmental organization, showed that 11.6% (3.0 million) of Australians were experiencing hypertension in 2022, with virtually equal rates of occurrence in males (11.7%) and females (11.6%). Therefore, the escalating occurrence of hypertension is the key factor boosting the growth of the renin-angiotensin system (RAS)-acting agents market.
Which Key Market Segments Comprise the Renin-Angiotensin-System (RAS)-Acting Agents Market and Drive Its Revenue Growth?
The renin-angiotensin-system (RAS)-acting agents market covered in this report is segmented –
1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes
2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics
4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users
Subsegments:
1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril
2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan
3) By Renin Inhibitors: Aliskiren
4) By Aldosterone Antagonists: Spironolactone, Eplerenone
5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Endothelin Receptor Antagonists, Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=23496&type=smp
Which Areas Are Leading Regions in the Renin-Angiotensin-System (RAS)-Acting Agents Market Expansion Across the Globe?
North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (RAS)-acting agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering the Renin-Angiotensin-System (RAS)-Acting Agents Market Direction?
Leading players in the renin-angiotensin system (RAS)-acting agents market are directing their efforts towards the creation of innovative renin-angiotensin system (RAS) inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors. This development is geared towards increasing effectiveness, reducing adverse effects, enhancing patient adherence, and targeting conditions such as hypertension, heart failure, and kidney diseases. ACE inhibitors are drugs that lower blood pressure by preventing the enzyme that transforms angiotensin I into angiotensin II, a compound that constricts blood vessels. For example, Proveca Ltd., a pharmaceutical firm based in the UK, received a grant from the European Commission for pediatric use marketing authorization (PUMA) in November 2023. This grant was for Aqumeldi (enalapril maleate) orodispersible tablets, designed to treat heart failure in children ranging from newborns to those under 18 years. Aqumeldi, an ACE inhibitor, aids child heart failure patients by inhibiting the ACE, blocking the transformation of angiotensin I into angiotensin II, hence broadening blood vessels, improving blood circulation, and lessening the heart’s burden.
View the full report here:
How Is the Renin-Angiotensin-System (RAS)-Acting Agents Market Conceptually Defined?
The renin-angiotensin system (RAS)-acting agents are a class of medications that regulate blood pressure, fluid balance, and vascular resistance by targeting various components of the renin-angiotensin system, which plays a crucial role in cardiovascular and renal function. These agents are commonly prescribed to treat conditions like hypertension, heart failure, and chronic kidney disease by either blocking the production of angiotensin II or inhibiting its effects on blood vessels.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23496
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
